Centralized procurement and heavy volume have become the highlights of the 2021 annual reports of some "barefoot" pharmaceutical companies

[Pharmaceutical Network Market Analysis] The reform of centralized pharmaceutical procurement with volume has entered a new stage of normalization and institutionalization
.

In this context, pharmaceutical companies have both joys and sorrows, and many of them have successfully taken advantage of centralized procurement to achieve rapid volume growth, which has become a highlight of the 2021 annual report
.

For example, Stellite, the global leader in the field of iodine contrast agents, released its 2021 annual report and its 2022 first quarterly report on the evening of April 25.
In 2021, its operating income will be 2.
000 billion yuan, a year-on-year increase of 46.
29%; its net profit attributable to the parent is 324 million yuan.
Yuan, a year-on-year increase of 35.
62%
.

In addition, in the first quarter of 2022, the company's performance continued to grow, achieving operating income of 517 million yuan, a year-on-year increase of 42.
08%; net profit attributable to the parent was 80.
2402 million yuan, a year-on-year increase of 24.
27%
.

 　　According to the data, Silitai is a company specializing in the R&D and production of X-CT non-ionic iodine contrast agent series and quinolone APIs and intermediates.
Behind the rapid growth of the company's performance, it is inseparable from the selection and collection of its preparation products.
volume
.

It is reported that in June 2021, the company won the bid for iohexol injection and iodixanol injection in the fifth batch of national centralized procurement, which will be implemented in October 2021.
From the fourth quarter, the company's preparation business will continue to increase and increase significantly The company's market share at the formulation level
.

The annual report data shows that in the fourth quarter of 2021, the company's operating income reached 689 million yuan, a year-on-year increase of 114.
94%, and the net profit attributable to the parent reached 104 million yuan, a year-on-year increase of 158.
84%.
Both revenue and net profit in a single quarter hit a record high
.

 　　In the 2021 annual board of directors’ business review released by Minovar recently, it mentioned, “In 2021, the company will win the bid for the fourth batch of national centralized drug procurement; atorvastatin calcium tablets, losartan Relay centralized procurement of potassium tablets and lisinopril tablets continued, and won the bids for the joint centralized procurement of 13 provinces in Guangdong, Jiangsu region, and Shandong region
.

In the context of the weakening of sales promotion under the policy of purchasing with volume, winning the bid for centralized procurement of medicines can not only bring new profit growth points for the company, increase market share and brand influence of the company, and promote the transformation of the company's preparations
.

It is reported that Minovar is a comprehensive international pharmaceutical technology manufacturing enterprise specializing in the research and development, production and sales of specialty raw materials (including intermediates) and finished drugs
.
The
company's 2021 annual report shows that during the reporting period, the total operating income was 12.
58 100 million yuan, an increase of 5.
43% over the same period of the previous year; the net profit attributable to shareholders of the listed company was 143 million yuan, a decrease of 8.
62% over the same period of the previous year
.

 　　On April 7, Huiyu Pharmaceutical released the 2021 annual report card.
During the reporting period, The company achieved operating income of 1.
827 billion yuan, a year-on-year increase of 33.
69%; net profit of 445 million yuan, a year-on-year increase of 30.
%
.

Regarding the reasons for the increase in performance, Huiyu Pharmaceutical stated that many products were selected for the fifth batch of national centralized procurement, It is worth mentioning that Huiyu Pharmaceutical is a "barefoot" pharmaceutical company participating in centralized procurement
.
In the 4 +
 　　7 centralized procurement pilot, Huiyu Pharmaceutical's pemetrexed disodium for injection successfully won the bid , and the original researcher Eli Lilly lost the bid, and Huiyu Pharmaceutical successfully opened up the hospital market space.
The number of hospital terminal sales increased from 82 at the end of 2018 to 2,444 in 2020, and the operating income of a single product also exceeded 1 billion yuan.
The pharmaceutical company has firmly taken the initiative in the pemetrexed market
.

In the follow-up centralized procurement, Huiyu Pharmaceutical also actively participated, and 5 products were successively included in the third and fifth batches of centralized procurement, and the products after the centralized procurement were included.
The market share has also increased significantly
.

 　　Of course, in addition to the companies whose performance has continued to rise through centralized procurement, there are also some companies that have to transform and innovate because of the decline in centralized procurement performance, such as Hengrui and Xinlitai
.

In general, centralized procurement is like a double-edged sword.
While providing more market opportunities for domestic pharmaceutical companies with technical strength and strong cost control capabilities, it also brings greater opportunities to some pharmaceutical companies.
The price pressure has forced these pharmaceutical companies to accelerate their transformation
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.